TOVX Insider Trading

Insider Ownership Percentage: 5.27%
Insider Buying (Last 12 Months): $106,380.00
Insider Selling (Last 12 Months): $0.00

Theriva Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at Theriva Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theriva Biologics Share Price & Price History

Current Price: $0.55
Price Change: Price Decrease of -0.05 (-8.33%)
As of 12/8/2023 09:58 PM ET

This chart shows the closing price history over time for TOVX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Theriva Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2023Steven A ShallcrossCEOBuy26,000$0.63$16,380.00236,000View SEC Filing Icon  
2/10/2023Steven A ShallcrossCEOBuy25,000$1.04$26,000.00210,000View SEC Filing Icon  
2/2/2023Steven A ShallcrossCEOBuy25,000$0.94$23,500.00185,000View SEC Filing Icon  
1/25/2023Steven A ShallcrossCEOBuy25,000$0.87$21,750.00160,000View SEC Filing Icon  
1/20/2023Steven A ShallcrossCEOBuy25,000$0.75$18,750.00135,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Theriva Biologics (NYSEAMERICAN:TOVX)

5.91% of Theriva Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Theriva Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2023Geode Capital Management LLC116,301$81K0.0%N/A0.769%Search for SEC Filing on Google Icon
5/12/2023BlackRock Inc.190,169$0.13M0.0%N/A1.258%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Theriva Biologics logo
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Read More on Theriva Biologics

Today's Range

Now: $0.55
Low: $0.55
High: $0.60

50 Day Range


52 Week Range

Now: $0.55
Low: $0.20
High: $1.26


37,500 shs

Average Volume

238,410 shs

Market Capitalization

$9.37 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Theriva Biologics?

Theriva Biologics' top insider investors include:
  1. Steven A Shallcross (CEO)
Learn More about top insider investors at Theriva Biologics.